Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing's sarcoma

Xiaomei Lei; Siping Yang; Yuanyuan Yang; Juan Zhang; Yue Wang; Minhui Cao

Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing's sarcoma

Am J Transl Res. 2019 Oct 15;11(10):6569-6576. eCollection 2019.

Authors

Xiaomei Lei¹, Siping Yang², Yuanyuan Yang¹, Juan Zhang³, Yue Wang¹, Minhui Cao⁴

Affiliations

¹ Department of Child Health Care, The Second Affiliated Hospital, Xi'an Jiaotong University Xi'an 710004, Shaanxi, China.
² Department of Medical Genetics, Xibei Maternal and Child Health Hospital Xi'an 710061, Shaanxi, China.
³ Department of Neonatal Paediatrics, Xibei Maternal and Child Health Hospital Xi'an 710061, Shaanxi, China.
⁴ Department of Child Health Care, Weinan Maternal and Child Health Hospital Weinan 714000, Shaanxi, China.

PMID: 31737208
PMCID: PMC6834508

Abstract

Ewing's sarcoma is one of leading cause of malignancy occurred in the children and adolescents worldwide. Given the emerging critical role of long noncoding RNA (lncRNA) in the human cancer, as well as Ewing's sarcoma, we aim to identify the biological role of DLX6-AS1 in the tumorigenesis. Results unveil that DLX6-AS1 expression was increased in the tissue sample and cells. Functionally, the silencing of DLX6-AS1 could repress the proliferation and accelerate the apoptosis of Ewing's sarcoma cells. Mechanically, DLX6-AS1 functioned as the sponge of miR-124-3p, and then miR-124-3p targeted the 3'-UTR of CDK4 mRNA, forming the DLX6-AS1/miR-124-3p/CDK4 regulatory pathway. In conclusion, the critical role of DLX6-AS1 might unveil a potential therapeutic target for Ewing's sarcoma.

Keywords: CDK4; DLX6-AS1; Ewing’s sarcoma; miR-124-3p.

Publication types

Retracted Publication